Following is one of the patent documents most requested by researchers using CAS electronic products.
|
CAS indexed 5 chemical substances from this document.
CAS subject entries for this document include: Mental and behavioral disorders; Headache; Nerve, disease; and 10 additional concepts. | |
CAPLUS COPYRIGHT 2007 ACS on STN
| TITLE:
| Preparation of topiramate sodium trihydrate as antiepileptic agents |
| INVENTOR(S):
| Almarsson, Orn; Remenar, Jules; Peterson, Matthew L. |
| PATENT ASSIGNEE(S):
| Transform Pharmaceuticals, Inc., USA |
| SOURCE:
| U.S., 31 pp. CODEN: USXXAM |
| LANGUAGE:
| English |
PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE
--------------- ---- -------- -------------------- --------
US 6559293 B1 20030506 US 2002-232589 20020903
US 2003166581 A1 20030904 US 2002-295995 20021118
US 6699840 B2 20040302
CA 2476422 A1 20030828 CA 2003-2476422 20030214
WO 2003070738 A2 20030828 WO 2003-US4357 20030214
WO 2003070738 A3 20030925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003211021 A1 20030909 AU 2003-211021 20030214
EP 1485388 A2 20041215 EP 2003-742731 20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003007919 A 20041221 BR 2003-7919 20030214
CN 1646538 A 20050727 CN 2003-808530 20030214
JP 2005524645 T 20050818 JP 2003-569645 20030214
US 2004053853 A1 20040318 US 2003-637829 20030808
US 2007026078 A1 20070201 US 2003-660202 20030911
US 2005169982 A1 20050804 US 2003-716976 20031119
WO 2004060347 A2 20040722 WO 2003-US41642 20031229
WO 2004060347 A3 20041104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2007015841 A1 20070118 US 2003-747742 20031229
MX 2004PA07968 A 20051018 MX 2004-PA7968 20040816
IN 2004KN01209 A 20060512 IN 2004-KN1209 20040819
US 2005070551 A1 20050331 US 2004-926842 20040826
NO 2004003819 A 20040913 NO 2004-3819 20040913
ZA 2004007377 A 20051004 ZA 2004-7377 20040914
US 2006140985 A1 20060629 US 2005-541703 20050708
US 2006223794 A1 20061005 US 2005-551014 20050929
ABSTRACT:
The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhyd., or amorphous forms thereof, as well as pharmaceutical compns. and pharmaceutical unit dosage forms contg. the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhyd., and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compns. comprising them. The invention also encompasses methods of treating or preventing in vivo patients a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.
Updated 8/24/2007 12:45:52 PM
